Key facts
- This page summarizes David S. Ege's Form 4 filing for Seres Therapeutics, Inc. (MCRB).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 31 Oct 2022, 19:37.
David S. Ege - 27 Oct 2022 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)
- Reporting relationship
- Executive Vice President and Chief Technology Officer
- Issuer ticker
- MCRB
- Reported as of
- 27 Oct 2022
- Net transaction value
- -$39,745
- SEC form
- 4
- Accepted by SEC
- 31 Oct 2022, 19:37:25 UTC
- Prior SEC filing
- 06 Jul 2022
- Next SEC filing
- 07 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas J. DesRosier, attorney-in-fact for David S. Ege
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David S. Ege filed Form 4 for Seres Therapeutics, Inc. (MCRB) on 31 Oct 2022.
Change
- Previous filing in this sequence was filed on 06 Jul 2022.
- Current net transaction value: -$39,745.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MCRB
transaction
Common stock
Award
- Transaction value
- $0
- Shares
- +20,000
- Change %
- +63%
- Price
- $0.000000
- Shares after
- 51,746
- Date
- 27 Oct 2022
- Ownership
- Direct
- Footnotes
- F1
MCRB
transaction
Common stock
Sale
- Transaction value
- $39,745
- Shares
- -5,012
- Change %
- -9.7%
- Price
- $7.93
- Shares after
- 46,734
- Date
- 31 Oct 2022
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On May 3, 2021, the reporting person was granted an award of 40,000 restricted stock units, which vest in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On October 27, 2022, the Issuer's Board of Directors determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 20,000 shares.
Footnote F2
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
SEC remarks
Executive Vice President and Chief Technology Officer